


Comprehensive genomic profiling (CGP) is driving a new standard of care

Enable simultaneous detection of multiple oncology biomarkers in a single next-generation sequencing test

CGP identifies actionable biomarkers that help optimize treatment



CGP offers substantial savings to the health care system

UP TO \$2.1 MILLION in potential savings as compared to exclusionary, sequential testing, and hotspot panels¹⁰

\$24 THOUSAND potential savings to the insurer per patient enrolled in a clinical trial²

CGP-based tumor profiling assays cover multiple relevant biomarkers



All known DNA and RNA variants




Genetic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI)



Biomarkers associated with approved and developing therapies across multiple tumor types

CGP consolidates testing for faster results using fewer samples

TODAY'S CHALLENGE: Increasing number of biomarkers plus limited biopsy sample



Consolidating biomarker detection into a single assay limits the input of precious biopsy sample, provides faster results, and reduces the need for rebiopsy¹⁰⁻¹²

References:
 1. Stransky N, et al. The landscape of kinase fusions in cancer. *Nat Commun.* 2014;5:4846.
 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. *Oncotarget.* 2015;6(24):20099-20110.
 3. Massard C, Michiels S, Ferte C, et al. High-throughput molecular profiling and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. *Cancer Discov.* 2017;7(6):586-595.
 4. Harris MH, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the individualized cancer therapy (iCat) study. *JAMA Oncol.* 2016;2(5):608-615.
 5. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. *JAMA Oncol.* 2016;2(5):616-624.
 6. Reitsma et al., 2019. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. *Journal of Managed Care & Specialty Pharmacy.* 2019;25(5):601-611.
 7. Sabatini LM, Mathews C, Ptak, S, et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. *J Mol Diag.* 2016;18(3):319-328.
 8. Clinical Trials. <https://clinicaltrials.gov>. Accessed May 22, 2019.
 9. U.S. Food and Drug Administration. <https://www.accessdata.fda.gov/scripts/cder/daf>. Accessed May 22, 2019.
 10. Pennel AP, Mutebi A, Zheng-Yi Z, et al. Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. *JCO Precis Oncol.* 2019. doi.org/10.1200/PO.18.00356.
 11. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed March 25, 2019.
 12. Lindeman NI, et al. Guideline from the college of American pathologists, the international association for the study of lung cancer, and the association of molecular pathology: updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. *J Thor Onc.* 2017;13(3):323-358.